Vimarsana
Biggest News Aggregation in the World

Page 3 - Eric Elenko News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Elenko. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Elenko Today - Breaking & Trending Today

Rockhopper loss widens; Synectics inks new contract - Vimarsana News

Rockhopper loss widens; Synectics inks new contract

- The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Rockhopper Exploration PLC - Salisbury, England-based...

Karuna Therapeutics (NASDAQ:KRTX) Now Covered by Wells Fargo & Company - Vimarsana News

Karuna Therapeutics (NASDAQ:KRTX) Now Covered by Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Karuna Therapeutics (NASDAQ:KRTX – Free Report) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $225.00 price target on the stock. A number of other research analysts have also recently commented on the stock. JPMorgan Chase […]

Karuna Therapeutics (NASDAQ:KRTX) PT Lowered to $235.00 at Royal Bank of Canada - Vimarsana News

Karuna Therapeutics (NASDAQ:KRTX) PT Lowered to $235.00 at Royal Bank of Canada

Karuna Therapeutics (NASDAQ:KRTX – Free Report) had its price objective decreased by Royal Bank of Canada from $249.00 to $235.00 in a research note published on Friday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. Several other equities analysts have also recently weighed in on the stock. Morgan Stanley […]

Royal Bank of Canada Cuts Karuna Therapeutics (NASDAQ:KRTX) Price Target to $235.00 - Vimarsana News

Royal Bank of Canada Cuts Karuna Therapeutics (NASDAQ:KRTX) Price Target to $235.00

Karuna Therapeutics (NASDAQ:KRTX – Free Report) had its target price cut by Royal Bank of Canada from $249.00 to $235.00 in a research report report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. KRTX has been the subject of a number of other research reports. HC Wainwright reaffirmed […]

Source: wkrb13.com
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome - Vimarsana News

PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Planning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome LYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients...